SCHEMBL24875342

SCHEMBL24875342

Cc1ccc(F)cc1C(C)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 3/20 0.44
AKR1C2 P52895 3/20 0.44
PTGS2 P35354 11/20 0.40
TDP1 Q9NUW8 1/20 0.40
PTGS1 P23219 10/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
FABP2 P12104 1/20 0.38
TSHR P16473 1/20 0.38
AKR1C4 P17516 1/20 0.38
ADRA2B P18089 1/20 0.38
CHRM3 P20309 1/20 0.38
HTR2C P28335 1/20 0.38
DRD3 P35462 1/20 0.38
AKR1C1 Q04828 1/20 0.38
SLC22A6 Q4U2R8 1/20 0.38
LMNA P02545 1/20 0.38
CYP1A2 P05177 1/20 0.38
MAPT P10636 1/20 0.38
CYP2C9 P11712 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2386163 0.86 AKR1C3 (0.47) AKR1C3AKR1C2PTGS2CYP2C9CYP2C19
SCHEMBL18322479 0.85 PTGS2 (0.42) AKR1C3AKR1C2PTGS2TDP1PTGS1
SCHEMBL15165860 0.83 CES2 (0.50) AKR1C3AKR1C2PTGS2PTGS1MEN1
SCHEMBL24875417 0.82 PSEN1 (0.45) PTGS2PTGS1MEN1KMT2ATSHR
SCHEMBL24875683 0.81 PSEN1 (0.48) AKR1C3AKR1C2PTGS2PTGS1MEN1
SCHEMBL30192806 0.81 PSEN1 (0.48) AKR1C3AKR1C2PTGS2PTGS1MEN1
SCHEMBL3670597 0.81 LMNA (0.44) AKR1C3AKR1C2PTGS2TDP1PTGS1
SCHEMBL7146617 0.81 LMNA (0.44) AKR1C3AKR1C2PTGS2TDP1PTGS1
SCHEMBL7152600 0.81 LMNA (0.44) AKR1C3AKR1C2PTGS2TDP1PTGS1
SCHEMBL24876443 0.80 PKM (0.39) AKR1C3AKR1C2PTGS2PTGS1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240376056-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. 2024-11-14 US disclosed
CN-118619931-A Aryl or heteroaryl derivative inhibitor, preparation method and application thereof 上海翰森生物医药科技有限公司 2024-09-10 CN disclosed
EP-4366829-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF Dice Alpha, Inc. (US) 2024-05-15 EP disclosed
CN-117957212-A IL-17A modulators based on phenylacetamide and uses thereof 戴斯阿尔法公司 2024-04-30 CN disclosed
WO-2023283453-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2023-01-12 WO disclosed
WO-2023283453-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF DICE ALPHA, INC. (US) 2023-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240376056-A1 PHENYL ACETAMIDE BASED IL-17A MODULATORS AND USES THEREOF IL17A, IL1A, IL2 AKR1C3 245/4885AKR1C2 297/4885PTGS2 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.